Clinical Phytoscience

, 5:36 | Cite as

In vivo and in vitro pharmacological activities of Tacca integrifolia rhizome and investigation of possible lead compounds against breast cancer through in silico approaches

  • Shahriar Ahmed
  • Ahmed Rakib
  • Md. Ashiqul Islam
  • Bibi Humayra Khanam
  • Farhana Binta Faiz
  • Arkajyoti Paul
  • Md. Nazim Uddin Chy
  • N. M. Mahmudul Alam Bhuiya
  • Mir Muhammad Nasir Uddin
  • S. M. Amanat Ullah
  • Md. Atiar Rahman
  • Talha Bin EmranEmail author
Open Access
Original contribution



The study was conducted to evaluate the analgesic, anti-inflammatory, antipyretic properties of ethanolic extract of Tacca integrifolia rhizome (EETI) in mice and cytotoxic effects in brine shrimp nauplii followed by a PASS prediction study for some isolated compounds of T. integrifolia. Additionally, this experiment included the in silico molecular docking and ADME/T property analyses of some phytochemicals.


Formalin- induced paw licking test and acetic acid-induced writhing test for analgesic activity, carrageenan-induced paw edema test for anti-inflammatory potential and Brewer’s yeast-induced pyrexia test for antipyretic activity were applied. Antinociceptive and antineoplastic activity for breast cancer were revealed with PASS program. Schrodinger suite 2015 was used to evaluate the binding interaction and ADME/T properties of selected phytoconstituents with estrogen receptor alpha.


In formalin-induced paw licking test, EETI at the doses of 200 and 400 mg/kg BW showed highly significant inhibition of writhing in both neurogenic and inflammatory phases. While EETI also exhibited highly significant, compared to control, writhing inhibition for both the doses in acetic acid-induced writhing test. Moderate anti-inflammatory effect at a dose of 400 mg/kg BW was noticed in paw-edema test. It also showed 77.51% of maximum antipyretic effect which was significantly effective compared to standard drug paracetamol (150 mg/kg) in Brewer’s yeast-induced pyrexia test. The EETI showed potential cytotoxic activity with LC50 value of 114.46 μg/mL. The PASS prediction revealed the potential antinociceptive and antineoplastic activity of target compounds. The compounds betulinic acid, quercetin-3-α-arabinoside, catsanogenin were found to be effective in molecular docking study.


It is evident that the EETI possesses highly significant analgesic activity with remarkable anti-inflammatory and antipyretic activity. The phytoconstituents have potential antinociceptive and antineoplastic (breast cancer) activity.

Graphical abstract


Tacca integrifolia Analgesic Anti-inflammatory Antipyretic PASS prediction Breast cancer Molecular docking 



Absorption, distribution, metabolism, and excretion


Body weight


Computer-aided drug discovery


Ethanolic extract of Tacca integrifolia rhizome


Estrogen receptor alpha


Lethal concentration




Non-steroidal anti-inflammatory drugs


Predict the activity spectra for substances




Vincristine sulphate


Pain, inflammation, and fever are the most common features people suffer from. The search for medication against nociception, inflammation, and pyrexia is increasing day by day due to the unwanted effects of existing anti-inflammatory, analgesics and antipyretic drugs [1]. Therefore, an alternative, safer and effective option is urgent to be searched. Plants and herbs have been used in Asian countries in traditional medicine to obtain analgesic, anti-inflammatory, and antipyretic effects [2, 3]. The brine shrimp lethality bioassay is an effective, quick and accessible that requires only a tiny amount of sample. This bio-analysis has a good contextual connection with cytotoxic activity in solid tumors and also possessed pesticidal activity. The bioassay also paves the way for the innovation of annonaceous acetogenins as an active antitumor agent [4].

Virtual screening has an especial meaning to understand the pharmacological effect of the phytoconstituents [5]. Depending on the structural formula of the substances, the prediction of activity spectra for substances (PASS) software predicted greater than 4000 bioactivities [6]. Breast cancer is the most general cancer among the women in Western countries. One of the main reason of breast cancer is estrogen receptor alpha (ER-α). Breast cancer is due to the overexpression of ER-α in a number of cases. Breast cancer begins in the inner lining of milk ducts and spread to the other parts of the body. In silico molecular biology uses computational models via computer simulation as used in systemic biology. As a result of a plenty of amount of data is now produced by molecular and experimental biologists, computational biology is surprisingly mandatory to handle it. Molecular docking analysis is also an in silico techniques, which methods are fundamental for the designing and planning of newer drug molecules using computer-aided drug discovery (CADD) techniques. A successful molecular docking must be able to dictate the native ligand pose with the binding site of the three-dimensional protein structure and associated with physicochemical interactions [7].

In this study, we evaluated the pharmacological attributes of Tacca integrifolia Ker Gawl. (Family: Taccaceae). The plant is a herb found in the forests of Chittagong, Chittagong Hill Tracts, and Moulavi Bazar, which is locally known as “Bara Hikand” and tubers are used as digestive and tonic [8]. In traditional medicine of Myanmar, its rhizomes have been used for the treatment of carbuncles, skin abrasion, skin diseases, and various kinds of cancers [9, 10, 11, 12]. In our current study, the crude rhizome extract of T. integrifolia were studied to explore their analgesic, anti-inflammatory, antipyretic, cytotoxic activities and also an in silico analysis of the antineoplastic (breast cancer) and antinociceptive activity using PASS program and molecular docking analysis with estrogen receptor alpha with the constituents obtained from the rhizome of T. integrifolia as well as the ADME/T analysis.

Materials and methods

Plant material

The rhizome of the plant of T. integrifolia was collected from Sreemangal Upazila, Moulvibazar, Sylhet, Bangladesh during the month of October and November and identified by Dr. Sheikh Bokhtear Uddin, Chittagong University Herbarium, Department of Botany, University of Chittagong, Chittagong-4331, Bangladesh. A voucher specimen (accession no. 1108) has been preserved in the institutional herbarium of the aforesaid Department.

Extraction of the plant material and sample preparation

At first, the rhizomes were washed with tap water carefully before cut into small pieces and then dried for 7 days in shade at 22–28 °C. Afterward, the pieces were grinded by a mechanical grinder and then passed through a size 60 mesh to obtain the fine powder. The materials were stored in an air-tight container. The resulting powder (600 g) was put in a clean round-bottom Erlenmeyer flask (5 L) and soaked in 4 L of ethanol for 15 days at room temperature with occasional shaking and stirring. The filtrate was collected through cotton plug followed by a Whatman no. 1 filter paper and evaporated by a Heidorph rotary evaporator at 45 °C. That left us a gummy concentrate of dark yellow brownish color crude extract (w/W, 4.08%). At last, the crude extract was dried by freeze drier and preserved at 4 °C [13].

Chemicals and reagents

The chemicals used were: ethanol, acetic acid (Merck, Germany), Diclofenac sodium, Paracetamol (Eskayef Bangladesh Limited, Tongi, Bangladesh), normal saline solution (Orion Infusion Limited, Bangladesh) and Tween-80 (Sigma-Aldrich). Rests of the chemicals were of BDH and E-Merck analytical grade. Brewer’s yeast was collected from the local market.

Experimental animals

For the experiment, adult Swiss albino mice (BALB/c) weighing between (12–30 g) of either sex were collected from animal house of International Centre for Diarrheal Disease and Research, Bangladesh (ICDDR, B), Dhaka. The animals were maintained under normal laboratory condition and kept in standard polypropylene cages at room temperature of (25 ± 2) °C and 60% to 65% relative humidity and provided with standard diet and water. Each group consists of five mice and to denote individual animal, they were marked as the group I, II, III, IV for test samples at the doses of 200 and 400 mg/kg BW and a normal control and positive control group was also maintained for whole intervention. Animals were handled and maintained according to the guidelines of Institutional Animal Ethics Committee of the Faculty of Biological Science of the University of Chittagong, Bangladesh (AERB/FBS/UC/02, 2015).

Acute toxicity test

Mice were divided into nine groups, each group consisting of five animals. Group I was given 1% Tween-80 in normal saline (2 mL/kg BW). The other eight groups (Groups II-IX) were administered, respectively, 100, 200, 400, 600, 800, 1000, 2000 mg of per kg BW. All animals were closely observed for the next 8 h to notice any behavioral changes or mortality and were kept under close observation for the next two weeks [14].

Phytochemical screening

EETI was qualitatively evaluated for the detection of alkaloids, glycosides, phenolics, terpenoids, carbohydrates, flavonoids, steroids, tannins, saponins following standard procedures [15].

Analgesic activity

Formalin-induced paw licking test

Animals were given 20 μL of 2.5% formalin solution (7% formaldehyde) made up in saline and injected intraperitoneally in the ventral surface of the right-hand paw. Animals were observed from 0 to 5 min (neurogenic phase) and 15–30 min inflammatory phase and the time spent licking the injected paw was recorded as indicative of nociception. The animals were given EETI at 200 and 400 mg/kg BW 1 h before, with the basis of a previous time response curve. Positive control group received standard drug Diclofenac sodium at the dose of 10 mg/kg BW [16, 17].

Acetic acid-induced writhing test

The analgesic activity of the extract was studied using the acetic acid-induced writhing model in mice [18]. The animals were divided into normal control, positive control and test groups with five mice in each group. The animals of test groups received test samples at the doses of 200 and 400 mg/kg BW. The positive control group received standard drug Diclofenac sodium at the dose of 10 mg/kg BW. Test samples were administered orally 30 min before intraperitoneal administration of 0.6% acetic acid and also Diclofenac sodium was administered 30 min before injection of acetic acid. After an interval of 5 min, the mice have observed for specific contraction of the body referred to as ‘writhing’ for the next 30 min.

Anti-inflammatory activity

Carrageen induced paw edema test

The anti-inflammatory activity was measured on mice of either sex (25–30 g). The animals were randomly divided into five groups each of six animals [19]. Group I was administered with normal saline (10 mL/kg), group II with Diclofenac sodium (10 mg/kg), rest of the groups were treated with EETI (200 and 400 mg/kg, i.p.). After 30 mins of the above intraperitoneal administration, carrageenan (1%, 0.05 mL) was injected subcutaneously in the subplantar tissue of the right hind paw of each mouse. The inflammation was measured using plethysmometer (LE 7500 plan lab S.L) immediately after injection of carrageenan and then 1, 2, 3 and 4 h. The average foot swelling in a drug-treated animal, as well as standard, was compared with that of control and the percent inhibition (anti-inflammatory activity) of edema was determined using the formula.
$$ Percent\kern0.34em inhibitation=\left(A-B\right)/A\times 100 $$

Where A represents edema volume of control and B as paw edema of tested group.

Antipyretic activity

Brewer’s yeast-induced pyrexia

The antipyretic activity of EETI was done by using BALB/c mice (25–30 g) of either sex. The animals were divided into five groups each of five mice. The normal body temperature of each mouse was recorded using a digital thermometer and then pyrexia was induced in all mice by injecting 20% aqueous suspension of Brewer’s yeast (10 mL/kg, s.c.). All groups were fasted overnight but allowed free accesses to drink water and after the 24 h rectal temperature of each mouse was recorded. The induction of pyrexia was confirmed by rising in temperature more than 0.5 °C, while animals showed a rise in temperature less than 0.5 °C were excluded from experiment [20]. Group I received saline (10 mL/kg) as a negative control, Group II received Paracetamol (150 mg/kg) as a standard drug while the remaining groups III and IV received 200 and 400 mg/kg, i.p. EETI respectively. After drugs administration, rectal temperature was again recorded periodically at 1, 2, 3 and 4 h of drugs administration. The percent reduction in pyrexia was calculated by the following formula.
$$ Percent\kern0.17em reduction=\frac{B- Cn}{B-A}\times 100 $$

Where, B represents temperature after pyrexia induction; Cn, temperature after 1, 2, 3 and 4 h and A, normal body temperature.

Cytotoxicity assay

Brine shrimp lethality bioassay

The brine shrimp lethality bioassay was carried out by the method described by Meyer et al., [21] for investigating the cytotoxicity of EETI. First of all, the dried extract preparations were dissolved in DMSO to obtain a solution of 10 mg/mL (1000 μg/mL) and from the stock solution, concentration of 800 μg/mL, 600 μg/ml, 400 μg/mL, 200 μg/mL, 100 μg/mL were made. The standard drug, Vincristine sulphate (VS) was used as positive control at concentrations 5 μg/mL – 0.156 μg/mL. 5.0 mL of artificial seawater (made by using sea salt 38 g/L and the pH was adjusted to 8.5 using 1 N NaOH) was added into all the test tubes. Brine shrimp (Artemisa salina) was used as a suitable monitor for the cytotoxicity screening. The eggs of the brine shrimps were collected from local aquarium shop (Chittagong, Bangladesh) and hatched in artificial seawater under constant air supply for 24 h under appropriate light. The hatched shrimps were allowed to grow by 48 h to get nauplii (Brine shrimp larvae). After 48 h, the active nauplii were attracted to one side in a glass Petri dish by using a micropipette. The nauplii were then separated from the eggs by aliquoting them in another glass petri dish containing artificial sea water and used for the assay. The suspension containing 10 nauplii was added into each test tube and was incubated at room temperature (25 ± 1 °C) under light for 12 h. The tubes were then assessed after 24 h and the number of surviving nauplii in each tube was counted by a 3X magnifying glass. Experiments were conducted along with VS in a set of three tubes per dose. The concentration that would kill 50% of the nauplii (LC50) was determined from a linear regression equation using the software “Microsoft Excel 2013”.

Selection of compounds for PASS prediction

The compounds betulinic acid, catsanogenin, quercetin-3-α-arabinoside, chantrieroside A, taccasuboside D, n-triacontanol, taccabulin A, taccalonolide AA, taccalonolide AB, taccalonolide Z were selected based on the availability in T. integrifolia as major compounds through literature survey [10, 22]. Amongst them, betulinic acid, catsanogenin, quercetin-3-α-arabinoside, chantrieroside A, taccasuboside D, n-triacontanol, taccabulin A, taccalonolide Z were collected from PubChem database and taccalonolide AA, taccalonolide AB were drawn using ChemDraw v 17.

In silico experiment to predict the activity spectra for substances (PASS)

The selected phytoconstituents i.e. betulinic acid, catsanogenin, quercetin-3-α-arabinoside, chantrieroside A, taccasuboside D, n-triacontanol, taccabulin A, taccalonolide AA, taccalonolide AB, taccalonolide Z [10, 22] were subjected for evaluating the antinociceptive and antineoplastic (breast cancer) activity with the help of the PASS program. This analysis predicts the spectrum of activity of a compound as probable activity (Pa) and probable inactivity (Pi) [23] based on the structure-activity relationship (SAR) analysis of the training set consisting of more than 2,05,000 compounds showing more than 3750 types of bioactivities. The Pa and Pi values lie between 0.000 to 1.000. If the value of Pa > Pi, then it assumed that the compound is experimentally active. When the Pa value is greater than 0.7, it means high pharmacological potentiality and the values following 0.5 < Pa < 0.7 demonstrates the considerable pharmacological activity experimentally. When the value of Pa < 0.5, the value exhibits a less pharmacological activity which may convey an opportunity for finding the new compound [24, 25].

In silico molecular docking analysis

Protein preparation

Three-dimensional crystal structures of estrogen receptor alpha (PDB ID: 3ERT) was downloaded in PDB format from the protein data bank [26]. After downloading as PDB format, the structure was prepared and refined using the Protein Preparation Wizard of Schrödinger-Maestro v10.1. Charges and bond orders were assigned, hydrogens were added to the heavy atoms, selenomethionines were converted to methionines, and all waters were deleted. Using force field OPLS_2005, minimization was carried out setting maximum heavy atom RMSD (root-mean-square-deviation) to 0.30 Å.

Ligand preparation

The target compound i.e. betulinic acid (PubChem CID: 64971), catsanogenin (PubChem CID: 436072), quercetin-3-α-arabinoside (PubChem CID: 5481224) were obtained from PubChem database. The 3D structures of the ligands were built by using Ligprep in Schrodinger Suite 2015 with the OPLS_2005 force field. The pH 7.0 ± 2.0 was used for the generation of ionization states of the compounds which used Epik 2.2 in the Schrödinger suite. Up to 32 possible stereoisomers per ligand were retained.

Receptor grid generation

Receptor grids were calculated for the prepared proteins for the observation of poses by various ligands bind within the active predicted site during the docking procedure. In Glide, grids were generated keeping the default parameters of van der Waals scaling factor 1.00 and charge cutoff 0.25 subjected to the OPLS_2005 force field. A cubic box of specific dimensions centered on the centroid of the active site residues was obtained for the receptor. The bounding box was set to 14 × 14 × 14 for docking experiments.

Glide standard precision (SP) ligand docking

SP flexible ligand docking was carried out in Glide of Schrödinger-Maestro v10.1 [27, 28] within which penalties were applied to non-cis/trans amide bonds. For ligand atoms, Van der partial charge cutoff and scaling factor were selected to be 0.15 and 0.80, respectively. Final scoring was done on energy-minimized poses and showed as Glide score. The best-docked pose with the lowest Glide score was recorded for each ligand.

ADME/T property analysis

Ligand base ADME/toxicity prediction

The QikProp module of the Schrödinger (Maestro v10.1) is a quick, precise, easy-to-use absorption, distribution, metabolism, and excretion (ADME) prediction program designed to get certain descriptors linked to ADME. It predicts both pharmacokinetic and physicochemical significant descriptors relevant properties. ADME properties ascertain drug-like activity of ligand molecules based on Lipinski’s rule of five. ADME/T properties of the compound (betulinic acic, quercetin-3-α-arabinoside, and catsanogenin) were analyzed by QikProp 3.2 module [29].

Statistical analysis

The results obtained were expressed as mean ± SEM (Standard error of mean) of five animals. For statistical analysis, ANOVA was followed by post hoc Dunnett’s test for multiple comparisons. Effects were considered to be significant at the p < 0.05 level. The statistical analysis was carried out in SPSS (version 16.0).


Acute toxicity test

The current study confirmed that oral administration of the EETI is safe as none of the doses (100, 200, 400, 600, 800, 1000, 2000 mg) exerted any mortality, morbidity or any kind of unwanted changes in behavior during the 8 h observation period.

Phytochemical screening

The phytochemical screening of EETI revealed that it possessed alkaloids, phenols, terpenoids, carbohydrates, flavonoids, steroids, saponins. The test also indicated the absence of glycosides, cardiac glycosides, tannins, and phlobatanins. The findings are summarized in Table 1.
Table 1

Observation and results of phytochemical screening

Secondary metabolite

Name of the test




1. Mayer’s test

White or creamy white precipitate


2. Hager’s test

Yellow crystalline precipitate


3. Wagner’s test

Brown or deep brown precipitate



General test

No yellow color

Cardiac glycosides

1. Legal’s test

No pink or red color

2. Baljet’s test

No yellow orange color


FeCl3 test

Violet color



Salkowsky test

Reddish color



1. Molisch Test

Red-violet layer at the interface between the acid (bottom) and aqueous (upper) layers


2. Fehling’s Test

Red precipitate



1. General test

A yellow colouration


2. Specific test

Orange to red color



Libermann-Burchard’s test

Greenish color



FeCl3 test

No brownish green color


Frothing test

Change is observed



General test

No Red precipitate formation

N.B. “+++” stands for the presence and “--” indicates the absence of secondary metabolites

Analgesic activity

Formalin-induced paw licking test

The results of the experiment exhibited that both 200 and 400 mg/kg doses of EETI showed highly significant (p < 0.001) percent inhibition of writhing in both neurogenic phase (42.40% and 63.25% respectively) and inflammatory phase (41.09% and 48.63% respectively) while standard drug Diclofenac sodium showed 73.67% and 66.56% in both phases respectively. The analgesic activity exerted by EETI was found highly significant (p < 0.001) compared to control and presented in Table 2.
Table 2

Effect of EETI on formalin induced writhing effect in mice


Dose mg/kg BW

Mean ± SEM (% Writhing)

1st phase (0–5 min)

%inhibition 1st phase (0–5 min)

Mean ± SEM (%Writhing) last phase (15–30 min)

%inhibition last phase (15–30 min)


56.6 ± 0.93

40.4 ± 1.03

Diclofenac sodium


14.90 ± 0.81***


13.60 ± 0.51***




32.6 ± 0.24***


23.80 ± 0.20***




20.8 ± 0.86***


20.75 ± 0.72***


SEM standard error of mean, n = 5, where n is the number of mice, % percentage. Values in the table are expressed as mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001 significantly different in comparison with control

Acetic acid-induced writhing test

EETI showed highly significant (p < 0.001) percent inhibition of writhing in Acetic acid-induced writhing test compared to control. Both the doses of EETI (200 and 400 mg/kg) exhibited 57.53 and 62.54% inhibition of writhing respectively where Diclofenac sodium (10 mg/kg) showed 63.01%. This confirms the significant analgesic activity of EETI. Table 3 represents the results of the test.
Table 3

Effect of EETI on acetic acid induced writhing test


Dose (mg/kg)

No. of writhing

% Inhibition


43.80 ± 0.97

Diclofenac sodium


16.20 ± 0.86***




18.60 ± 0.51***




16.41 ± 0.39***


SEM standard error of mean, n = 5, where n is the number of mice. Values in the figure are expressed as mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001 significantly different in comparison with control. The data was analyzed by ANOVA followed by Dunnett’s test

Anti-inflammatory activity

Carrageen induced paw edema

The results of the experiment using Carrageenan-induced paw edema to evaluate anti-inflammatory effect of EETI are presented in Table 4. Both the doses (200 and 400 mg/kg) of EETI exerted marked (p < 0.01) anti-inflammatory potential. The percent inhibition of paw volume is presented in Fig. 1. However, maximum 60.90% of inhibition was showed by 400 mg/kg dose of EETI at the 3 h, while Diclofenac sodium (10 mg/kg) showed 75.60% inhibition at the same time period compared to control.
Table 4

Effect of EETI on carrageenan-induced paw edema test


Dose (mg/kg)

0 h

1 h

2 h

3 h

4 h


10 mL

0.2161 ± 0.23

0.2181 ± 0.11

0.2196 ± 0.19

0.2041 ± 0.13

0.2039 ± 0.17

Diclofenac sodium


0.2179 ± 0.24

0.1486 ± 0.03*

0.0981 ± 0.09**

0.0498 ± 0.04**

0.0622 ± 0.03**



0.2141 ± 0.22

0.2021 ± 0.10

0.1903 ± 0.18

0.1498 ± 0.36*

0.1581 ± 0.15



0.2191 ± 0.21

0.1681 ± 0.28*

0.1246 ± 0.31*

0.0797 ± 0.18**

0.0941 ± 0.38**

SEM standard error of mean, n = 5. Values in the table are expressed as mean ± SEM, *p < 0.05, **p < 0.01 significantly different in comparison with control. The data was analyzed by ANOVA followed by Dunnett’s test

Fig. 1

Anti-inflammatory effect of EETI on Carrageenan-induced paw edema test. Each point percent inhibition of paw edema after 1, 2, 3 and 4 h of treatment. The data was analyzed by ANOVA followed by Dunnett’s test. Asterisks indicated statistically significant values from control. *p < 0.05, **p < 0.01

Antipyretic activity

Brewer’s yeast-induced pyrexia

Hyperthermia, induced by yeast, was markedly (p < 0.01) lessened by the EETI compared to control. Table 5 showed the results which indicated that the percent inhibition was dose-dependent and remained significant up to 3 h of administration. The maximum antipyretic effect 77.51% was observed at 400 mg/kg while the standard drug Paracetamol (150 mg/kg) showed 90.33% inhibition. The percent inhibition results are presented in Fig. 2.
Table 5

Effect of EETI on Yeast-induced pyrexia in mice




Rectal temperature (°C)

Normal (A) (Before yeast injection)

After administration of drug

after 24 h (B)

1st h (C1)

2nd h (C2)

3rd h (C3)

4th h (C4)


10 mL

36.65 ± 0.10

38.91 ± 0.33

38.81 ± 0.20

38.77 ± 0.10

38.67 ± 0.19

38.68 ± 0.20



37.07 ± 0.07

39.45 ± 0.06

38.19 ± 0.02**

37.82 ± 0.05**

37.30 ± 0.01**

37.34 ± 0.27**



37.04 ± 0.05

39.72 ± 0.45

39.42 ± 0.25

38.98 ± 0.21*

38.02 ± 0.12**

38.03 ± 0.14**



37.02 ± 0.10

39.82 ± 0.21

39.32 ± 0.33

38.72 ± 0.13*

37.65 ± 0.45**

37.72 ± 0.11**

SEM standard error of mean, n = 5, where n is the number of mice. Values in the figure are expressed as mean ± SEM, *p < 0.05, **p < 0.01 significantly different in comparison with control. The data was analyzed by ANOVA followed by Dunnett’s test

Fig. 2

Antipyretic effect of EETI in mice. Bar presents the percent inhibition of pyrexia after 1, 2, 3 and 4 h of the treatment with Paracetamol (150 mg/kg) and EETI (200 and 400 mg/kg). *p < 0.05, **p < 0.01, significantly different in comparison with control. The data was analyzed by ANOVA followed by Dunnett’s test

Cytotoxic activity

In brine shrimp lethality bioassay, the EETI exhibited an optimistic result in comparison with the positive control vincristine sulphate. By plotting the concentration versus percentage of mortality for all test samples showed an approximate linear correlation. From the graph, the median lethal concentration (LC50) was calculated. Cytotoxic effect of the extract was summarized in Fig. 3. The LC50 for the EETI was found 114.46 μg/mL respectively, and that of the standard VS was 0.56 μg/mL. DMSO was used as negative control for validating this method.
Fig. 3

Cytotoxic effect of EETI in brine shrimp nauplii . Effects of various concentrations of ethanol extract of T. integrifolia rhizomes on the viability of brine shrimp nauplii after 24 h incubation. Percentage mortality of brine shrimps of ethanolic extract of rhizomes of T. integrifolia. Data are shown as mean ± SEM of 10 shrimps for each concentration

In silico pass prediction

A total of 10 phytoconstituents namely betulinic acid, catsanogenin, quercetin-3-α-arabinoside, chantrieroside A, taccasuboside D, n-triacontanol, taccabulin A, taccalonolide AA, taccalonolide AB, taccalonolide Z were screened for the antineoplastic (breast cancer) and antinociceptive effects by the aid of the PASS program and the results were used in a resilient manner. The selected compounds exhibited higher Pa than Pi (Table 6). The compounds betulinic acid and catsanogenin showed highest Pa value for both antineoplastic activities for breast cancer and antinociceptive activity (Table 6). Quercetin-3-α-arabinoside has exhibited a considerable pharmacological activity for breast cancer (Pa = 0.628).
Table 6

Pass prediction of betulinic acid, catsanogenin, quercetin-3-α-arabinoside, chantrieroside A, taccasuboside D, n-triacontanol, taccabulin A, taccalonolide AA, taccalonolide AB, taccalonolide Z for antineoplastic (breast cancer) and antinociceptive activity


Pass prediction of antineoplastic (breast cancer) activity

Pass prediction of antinociceptive activity





Betulinic acid















Chantrieroside A





Taccasuboside D








Taccabulin A





Taccalonolide AA



Taccalonolide AB



Taccalonolide Z



In silico molecular docking analysis

At present, computational techniques have been effectively used for the prediction of drug-target binding affinity and to understand the possible molecular mechanism of the pharmacological responses. Keeping this in view, in silico molecular docking study between ligands and protein were performed to understand comprehensibly that mechanisms and to confirm their findings with the experimental results. In this study, 10 major compounds of T. integrifolia were tested against the target enzymes (Human estrogen receptor alpha, PDB ID: 3ERT) and the docking scores obtained for the best-ranked pose for all compounds have been reported in Table 7.
Table 7

Docking result of betulinic acid, catsanogenin and quercetin-3-α-arabinoside with estrogen receptor alpha (ER-α) (PDB: 3ERT) in kcal/mol

Compound name

Docking score

Glide e model

Glide energy

Betulinic acid


− 47.916




− 52.085

− 41.136



− 68.354

− 49.43

Chantrieroside A

Taccasuboside D


Taccabulin A

Taccalonolide AA

Taccalonolide AB

Taccalonolide Z

The best pose found for betulinic acid in the enzymatic pocket of Human estrogen receptor alpha was stabilized by the formation of two hydrogen bonds (H-bonds) with Glu380 and Leu536 with a docking score − 4.599 Kcal/mol as shown in Fig. 4. Additionally, Catsanogenin binds to the enzymatic pocket of the Human estrogen receptor alpha by forming a series of H-bonds with Glu380, Cys530, Met528 residues (docking score: − 4.814 Kcal/mol), while Quercetin-3-α-arabinoside interacted with the same enzymatic pocket by establishing 3 H-bonds with Met522, Asp351, and Val534 (docking score: − 6.511 Kcal/mol). On the other hand, the remaining phytocompounds didn’t show any interactions with Human estrogen receptor alpha for cytotoxic activity.
Fig. 4

Docking results. Best ranked pose of Betulinic acid (a), Catsanogenin (b), and Quercetin-3-α-arabinoside (c) in the binding pocket of estrogen receptor alpha (PDB: 3ERT) and 2D representation of key interactions in the binding pocket for Betulinic acid (d), Catsanogenin (e), and Quercetin-3-α-arabinoside (f)

ADME/T property analysis

Ligand based ADME/toxicity prediction

The drug similar attitude of the ligand molecule was determined using ADME properties by QikProp module of Schrodinger Maestro v10.1. The ADME/T properties of betulinic acid, quercetin-3-α-arabinoside and catsanogenin were determined with QikProp module of Schrodinger, shown in Table 8. The selected properties are known to affect the cell permeation, metabolism, and bioavailability. Predicted properties of betulinic acid were in the range for satisfying the Lipinski’s rule of five to be recognized as drug-like potential. Betulinic acid and catsanogenin possessed a higher rate of human oral absorption.
Table 8

ADME and drug likeness properties of betulinic acid, quercetin-3-α-arabinoside and catsanogenin by QikProp

Compound name


HB donorb

HB acceptorc





%Human Oral Absorptionh

Betulinic acid



























aMolecular weight (acceptable range: < 500). bHydrogen bond donor (acceptable range: ≤5). cHydrogen bond acceptor (acceptable range: ≤10). dTotal Solvent Accessible Surface Area in using a probe with a 1.4 radius (acceptable range: 300–1000). ePredicted octanol/water partition coefficient (acceptable range: − 2–6.5). fPredicted blood-brain partition co-efficient (acceptable range: −3-1.2). gPredicted aqueous solubility, S in mol/dm− 3 (acceptable range: −6.5–0.5). hPredicted human oral absorption on 0 to 100% scale (< 25% is poor and > 80% is high)


To evaluate both central and peripheral analgesic activity along with the antipyretic activity of EETI formalin-induced paw licking test, acetic acid-induced writhing test and Brewer’s yeast-induced pyrexia test were conducted respectively. Formalin-induced paw licking test is an established method for evaluating central analgesic activity. In this test, two distinguishable different stimuli involve and thus the animals exhibits two phases of pain actions [30]. The early phase may include the nociceptors and the direct action of formalin in it and centrally acting analgesics suppress it. On the contrary, the late phase occurs as a result of the inflammation which is mediated by different inflammatory mediators like prostaglandins, bradykinin or histamine and subdued by centrally acting analgesics, sometimes with steroids and sometimes by non-steroidal anti-inflammatory drugs (NSAIDs). In this study, both in neurogenic phase and inflammatory phase, the two doses 200 mg/kg and 400 mg/kg, EETI produced highly significant (p < 0.001) effects in the formalin test. That means the plant extracts may pose its analgesic activity by centrally acting or peripheral mechanisms. This observed analgesic activity may be as a result of phytochemicals presents in the extracts [31].

Out of several different modes to select administrative doses for animal models, selection based on acute toxicity-test and LD50 value is our prime choice. According to the theory, prior to intervention, a group of animals is received a gradually increased dose to apprehend a toxic dose which leads to calculate LD50. The effective therapeutic dose was taken as one tenth of the median lethal dose (LD50 > 2.0 g/kg) [32] which is practically justified using a logarithmically linked dose. Additionally, the reference control is a pure single molecule drug which is established as 10 mg/kg BW for its effectiveness. On the contrary, the crude extract is usually reported to have relatively lower absorption that is harmonized with it LD50 based relatively higher doses. Indeed, ethanol is no doubt a very good solvent for polyphenols and flavonoids extraction and is safe for human consumption [33, 34]. Our target was to collect the polyphenols-rich extract probably having the target biological effects [35, 36] designed for this research. Methanol has been avoided as it is generally found to be more efficient in extraction of lower molecular weight polyphenols which suffers from our target.

The peripheral analgesic activity is determined by the administration of vicious chemicals such as acetic acid intraperitoneally which resulting writhing response of mouse [37]. Several inflammatory mediators e.g. prostaglandins, histamine and bradykinin are induced by the intraperitoneal administration of acetic acid thus stimulating pain sensation [38, 39]. At the time of the writhing test, the level of prostaglandins, especially PGE2 and PGF2α and also the lipoxygenase products in the peritoneal fluids are markedly raised [40, 41]. Analgesic activity is possessed by the extracts if the extracts are able to recede the acetic acid-induced writhing in mice. In our observation, EETI showed highly significant (p < 0.001) percent inhibition of writhing in the acetic acid-induced writhing test. The EETI of the plant might be hindered the biosynthesis, release and/or action of the chemical agent like prostaglandins and leukotrienes from cyclo-oxygenase and lipo-oxygenase pathways, respectively and thus exhibiting analgesic property by inhibiting the pain sensation. The presence of alkaloids may avail this analgesic activity [42].

Carrageenan-induced paw edema test is a well-established and most widely used test to evaluate the anti-inflammatory potential of plants and drugs [43, 44]. Inflammation is a complex process as it involves the activation of various mediators like prostaglandins, kinins, platelet activating factors, leukotrienes, neutrophils and several cytokines including interleukins and tumor necrosis factors [45]. These mediators play an important role in the development of edema [46]. The administration of carrageenan gives the rise of bradykinin along with prostaglandin and other autacoids. Neutrophils and free radicals like hydrogen peroxide, superoxide, and hydroxyl radicals are also released by the carrageenan and play a significant role in the formation of edema [47, 48]. However, Carrageenan-induced paw edema is a biphasic event. The release of kinins, serotonin, and histamine occurs in the initial phase whereas prostaglandins, lysosomes and protease are released in the later phase. This later phase is sensitive to most clinically effective anti-inflammatory drugs [49]. The results of the current study showed that EETI possessed marked anti-inflammatory potential as its 400 mg/kg dose significantly inhibited inflammation (From a 2nd hour and onwards) induced by carrageenan injection. This indicated that EETI probably inhibited either cyclooxygenase and/or lipo-oxygenase enzyme or the synthesis, release, and action of above inflammatory mediators.

Pyrexia is inclined by subcutaneous injection of Brewer’s yeast as it uplifts the prostaglandin synthesis and considered as an important test for the identification of antipyretic effect on several plant materials and other synthetic drugs [19, 50]. Yeast-induced pyrexia is known as pathogenic fever which causes the synthesis of prostaglandins [51]. Obstruction of cyclo-oxygenase pathways leads to the curbing of prostaglandins and might be a possible mechanism of antipyretic activity as that of several non-steroidal anti-inflammatory drugs (NSAIDs). Blocking of different mediators for pyrexia are responsible for the antipyretic effect [52]. In this experiment, the intraperitoneal administration of EETI markedly (p < 0.01) lessened the yeast-induced hyperthermia in the feverish mice. Thus it can be presumed that EETI has certain pharmacologically active components which are responsible for the interference with the release of prostaglandins and by this way, reducing the body temperature.

Plant material toxicity is an important concernment for researchers and scientists [53, 54, 55, 56]. Due to this purpose, the cytotoxicity assay was performed in this study for the determination of toxicity profile of the EETI using brine shrimp lethality bioassay. According to Meyer et al. 1982, crude extracts and pure substances are toxic if the LC50 value is less than 1000 μg/mL and non-toxic if the value of LC50 is greater than 1000 μg/mL. In this experiment, the LC50 value for the EETI of T. integrifolia was found 114.46 μg/mL respectively and hence the outcome demonstrated that the rhizome extract is cytotoxic. Further investigation and literature survey prove that the rhizome extract contains some cytotoxic compounds.

In the purpose of accelerating the potent natural product research, computer-aided drug discovery (CADD) program PASS was used for the biological activity prediction. Pass prediction tool was consists of using 20,000 principal compounds [57]. The results of the prediction were demonstrated as Pa and Pi ratio. In this experiment, betulinic acid and catsanogenin have shown the maximum Pa value for both antineoplastic and analgesic activities. Quercetin-3-α-arabinoside possessed a higher rate of antineoplastic activity against breast cancer showing the Pa value of 0.628. Among the 10 compounds our docking study suggests that betulinic acid, catsanogenin, and quercetin-3-α-arabinoside may be the responsible bioactive phytochemicals for potential cytotoxic or anticancer activities of the plant. According to the Glide Docking score and Glide energy we can see that among these three compounds quercetin-3-α-arabinoside is the potent compound, although further in vivo studies are needed to explore their in-depth mechanism of action. This finding is also consistent with the literature data since an earlier report stated that both compounds (betulinic acid and quercetin-3-α-arabinoside) have anticancer properties.

Breast cancer is the most common tumor for cancer progression in the industrialized countries and it is one of the most important reasons for cancer-related mortality [58]. Tumor expression of estrogen receptors (ERs) predicts the response to treatment of breast cancer as estrogen is concerned physiologically with a greater risk for breast and endometrial cancer [59]. The change of activity of ERs induces cancer regression especially estrogen receptor alpha (ER-α) [60]. ER-α is a carping regulatory gene for the improvement of the breast cancer and its expression is crucial for tumor progression. In this study, components from the rhizome of plant T. integrifolia i.e. betulinic acid, catsanogenin, quercetin-3-α-arabinoside were investigated for the interaction with estrogen alpha receptor ligand binding domain. All the compounds possessed a higher attraction towards the ligand binding domain of estrogen alpha receptor and the blockade may be due to strong ligand-protein complex formation. The compound quercetin-3-α-arabinoside showed highest docking score of − 6.286 kcal/mol. For natural product chemists, the necessity of virtual screening is significant for the quest of active principles with attractive ADME/T profiles which have been separated before but not analyzed for activity against specific drug targets [22]. The ADME and toxicity profiles of the compounds betulinic acid, catsanogenin, quercetin-3-α-arabinoside are moderate and they are thought to be potential drug in terms of better pharmacokinetic parameters with the less amount of toxicity.


The investigation indicated that EETI is safe to show significant analgesic activity and moderate anti-inflammatory, and antipyretic activity. However, the extract is cytotoxic to the brine shrimps naupliis. Moreover, from the in silico PASS prediction, the isolated phytoconstituents are greatly impacted for analgesic and anticancer activity against breast cancer. But, quercetin-3-α-arabinoside could be chosen based for its best fitness score and betulinic acid seems the highest capability to be absorbed upon oral administration.



The authors are grateful to the Department of Pharmacy, Faculty of Biological Sciences, University of Chittagong, Chittagong-4331, Bangladesh, for providing the facilities to conduct this research work. The authors are also thankful to the Taxonomist and Professor, Dr. Shaikh Bokhtear Uddin, Department of Botany, University of Chittagong, Bangladesh, for identifying all the plants.


All authors read the manuscript and approved it for submission. No part of the manuscript has been published before, nor is any part of it under consideration for publication at another journal.

Authors’ contributions

This work was carried out in collaboration between all authors. All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission. Authors SA and AR collected the plant leaves and prepared the extracts and fractions. SA, AR, MAI, BHK and FBF carried out the study design, performed the experiments, data collection, data interpretation, manuscript preparation, statistical analysis. Authors AP, MNUC and SMAU has arranged the in silico docking study. NMMAB, MMNU, MAR, and TBE designed and planned the studies, supervised the experiments. TBE also acted for all correspondences. TBE and MAR participated in the manuscript draft and has thoroughly checked and revised the manuscript for necessary changes in format, grammar and English standard. All authors read and approved the final version of the manuscript.


This work is managed to perform with the individual funding of all authors.

Ethics approval and consent to participate

This study was approved by ethical research committee of the Faculty of Biological Science of the University of Chittagong, Bangladesh (AERB/FBS/UC/02, 2015).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.


  1. 1.
    Weng X, Smith T, Sathish J, Djouhri L. Chronic inflammatory pain is associated with increased excitability and hyperpolarization-activated current (Ih) in C- but not Aδ-nociceptors. Pain®. 2012;153(4):900–14.CrossRefGoogle Scholar
  2. 2.
    Adnan MSA, Al-Amin MM, Uddin MMN, Shohel M, Bhattacharjee R, Hannan J, Das BK. Analgesic, anti-inflammatory and antipyretic effects of Ixora coccinea. J Basic Clin Physiol Pharmacol. 2014;25(4):423–8.Google Scholar
  3. 3.
    Zaveri M, Gohil P, Jain S. Immunostimulant activity of n-butanol fraction of root bark of Oroxylum indicum vent. J Immunotoxicol. 2006;3(2):83–99.PubMedCrossRefGoogle Scholar
  4. 4.
    Mclaughlin JL, Rogers LL, Anderson JE. The use of biological assays to evaluate botanicals. Drug Inf J. 1998;32(2):513–24.CrossRefGoogle Scholar
  5. 5.
    Parasuraman S. Prediction of activity spectra for substances. J Pharmacol Pharmacother. 2011;2(1):52.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Filimonov D, Lagunin A, Gloriozova T, Rudik A, Druzhilovskii D, Pogodin P, Poroikov V. Prediction of the biological activity spectra of organic compounds using the PASS online web resource. Chem Heterocycl Com. 2014;50(3):444–57.CrossRefGoogle Scholar
  7. 7.
    Guedes IA, de Magalhães CS, Dardenne LE. Receptor–ligand molecular docking. Biophys Rev. 2014;6(1):75–87.PubMedCrossRefGoogle Scholar
  8. 8.
    Yusuf M, Begum J, Hoque MN, Choudhury JU. Medicinal plants of Bangladesh-Revised and Enlarged. Chittagong: Bangladesh Coun. Sci. Ind. Res. Lab; 2009.Google Scholar
  9. 9.
    Ghani A. Medicinal plants of Bangladesh: chemical constituents and uses. Dhaka: Asiatic Society of Bangladesh; 1998.Google Scholar
  10. 10.
    Kitjaroennirut N, Jansakul C, Sawangchote P. Cardiovascular effects of Tacca integrifolia Ker-Gawl extract in rats. Songklanakarin J Sci Technol. 2005;27(2):281–9.Google Scholar
  11. 11.
    Razak M-FA, Aidoo KE, Candlish AG. Mutagenic and cytotoxic properties of three herbal plants from Southeast Asia. Trop Biomed. 2007;24(2):49–59.Google Scholar
  12. 12.
    Shwe HH, Aye M, Sein MM, Htay KT, Kreitmeier P, Gertsch J, Reiser O, Heilmann J. Cytotoxic steroidal saponins from the rhizomes of Tacca integrifolia. Chem Biodivers. 2010;7(3):610–22.CrossRefGoogle Scholar
  13. 13.
    Haque M, Haque M, Rahman M, Khondkar P. Antibacterial and cytotoxic activities of Capparis zeylanica Linn roots. Ars Pharmaceutica. 2008;49(1):31–7.Google Scholar
  14. 14.
    Faisal M, Hossain AI, Rahman S, Jahan R, Rahmatullah M. A preliminary report on oral glucose tolerance and antinociceptive activity tests conducted with methanol extract of Xanthosoma violaceum aerial parts. BMC Complement Altern Med. 2014;14(1):335.Google Scholar
  15. 15.
    Ghani A. Medicinal plants of Bangladesh with chemical constituents and uses. vol. 5: Asiatic Society of Bangladesh; Dhaka: Bangladesh; 2003.Google Scholar
  16. 16.
    Santos A, Calixto J. Further evidence for the involvement of tachykinin receptor subtypes in formalin and capsaicin models of pain in mice. Neuropeptides. 1997;31(4):381–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Santos AR, De Campos RO, Miguel OG, Filho VC, Siani AC, Yunes RA, Calixto JB. Antinociceptive properties of extracts of new species of plants of the genus Phyllanthus (Euphorbiaceae). J Ethnopharmacol. 2000;72(1–2):229–38.PubMedCrossRefGoogle Scholar
  18. 18.
    Süleyman H, Demirezer LÖ, Kuruüzüm A, Banoğlu Z, Göçer F, Özbakir G, Gepdiremen A. Antiinflammatory effect of the aqueous extract from Rumex patientia L. roots. J Ethnopharmacol. 1999;65(2):141–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Khan I, Nisar M, Ebad F, Nadeem S, Saeed M, Khan H, Khuda F, Karim N, Ahmad Z. Anti-inflammatory activities of Sieboldogenin from Smilax china Linn.: experimental and computational studies. J Ethnopharmacol. 2009;121(1):175–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Kang J, Khan M, Park N, Cho J, Lee M, Fujii H, Hong Y. Antipyretic, analgesic, and anti-inflammatory activities of the seaweed Sargassum fulvellum and Sargassum thunbergii in mice. J Ethnopharmacol. 2008;116(1):187–90.PubMedCrossRefGoogle Scholar
  21. 21.
    Meyer B, Ferrigni N, Putnam J, Jacobsen L, Nichols D, McLaughlin JL. Brine shrimp: a convenient general bioassay for active plant constituents. Planta Med. 1982;45(5):31–4.PubMedCrossRefGoogle Scholar
  22. 22.
    Liu ZH, Yan H, Liu HY. Chemical constituents and their bioactivities of plants of Taccaceae. Chem Biodivers. 2015;12(2):221–38.CrossRefGoogle Scholar
  23. 23.
    Mojumdar M, Kabir MSH, Hasan MS, Ahmed T, Rahman MR, Akter Y, Rahman MM. Molecular docking and pass prediction for analgesic activity of some isolated compounds from Acalypha indica L and ADME/T property analysis of the compounds. World J Pharma Res. 2016;5(7):1761–70.Google Scholar
  24. 24.
    Goel RK, Singh D, Lagunin A, Poroikov V. PASS-assisted exploration of new therapeutic potential of natural products. Med Chem Res. 2011;20(9):1509–14.CrossRefGoogle Scholar
  25. 25.
    Khurana N, Ishar MPS, Gajbhiye A, Goel RK. PASS assisted prediction and pharmacological evaluation of novel nicotinic analogs for nootropic activity in mice. Eur J Pharmacol. 2011;662(1–3):22–30.PubMedCrossRefGoogle Scholar
  26. 26.
    Berman HM, Battistuz T, Bhat TN, Bluhm WF, Bourne PE, Burkhardt K, Feng Z, Gilliland GL, Iype L, Jain S. The protein data bank. Acta Crystallogr D Biol Crystallogr. 2002;58(6):899–907.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004;47(7):1739–49.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein−ligand complexes. J Med Chem. 2006;49(21):6177–96.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Natarajan A, Sugumar S, Bitragunta S, Balasubramanyan N. Molecular docking studies of (4 Z, 12 Z)-cyclopentadeca-4, 12-dienone from Grewia hirsuta with some targets related to type 2 diabetes. BMC Complement Altern Med. 2015;15(1):73.Google Scholar
  30. 30.
    Uddin MMN, Kabir MSH, Hasan M, Al Mahmud Z, Bhuiya NMA, Ahmed F, Hasan MR, Hosen MT, Alam MS. Assessment of the antioxidant, thrombolytic, analgesic, anti-inflammatory, antidepressant and anxiolytic activities of leaf extracts and fractions of Tetracera sarmentosa (L.) Vahl. J Basic Clin Physiol Pharmacol. 2018;29(1):81–93.PubMedCrossRefGoogle Scholar
  31. 31.
    Zulfiker A, Rahman MM, Hossain MK, Hamid K, Mazumder M, Rana MS. In vivo analgesic activity of ethanolic extracts of two medicinal plants-Scoparia dulcis L. and Ficus racemosa Linn. Biol Med. 2010;2(2):42–8.Google Scholar
  32. 32.
    Zaoui A, Cherrah Y, Mahassini N, Alaoui K, Amarouch H, Hassar M. Acute and chronic toxicity of Nigella sativa fixed oil. Phytomedicine. 2002;9:69–74.PubMedCrossRefGoogle Scholar
  33. 33.
    Diem Do Q, Angkawijaya AE, Tran-Nguyen PL, Huynh LH, Soetaredjo FE, Ismadji S, Ju YH. Effect of extraction solvent on total phenol content, total flavonoid content, and antioxidant activity of Limnophila aromatica. J Food Drug Anal. 2014;22:296–302.PubMedCrossRefGoogle Scholar
  34. 34.
    Bonoli M, Verardo V, Marconi E, Caboni MF. Antioxidant phenols in barley (Hordeum vulgare L.) flour: comparative spectrophotometric study among extraction methods of free and bound phenolic compounds. J Agric Food Chem. 2004;52:5195e200.PubMedCrossRefGoogle Scholar
  35. 35.
    Rajnarayana K, Reddy MS, Chaluvadi MR, Krishna DR. Biflavonoids classification, pharmacological, biochemical effects and therapeutic potential. Indian J Pharmacol. 2001;33:2–16.Google Scholar
  36. 36.
    Tiwari P, Kumar B, Kaur M, Kaur G, Kaur H. Phytochemical screening and extraction: a review. Int Pharmaceutica Sciencia. 2011;1(1):98–106.Google Scholar
  37. 37.
    Trongsakul S, Panthong A, Kanjanapothi D, Taesotikul T. The analgesic, antipyretic and anti-inflammatory activity of Diospyros variegata Kruz. J Ethnopharmacol. 2003;85(2–3):221–5.PubMedCrossRefGoogle Scholar
  38. 38.
    Khan MA, Rahman AA, Nahar L, Islam MB, Alam AHMK. In vivo analgesic and CNS depressant activities of antioxidative stem bark fraction of Morus alba L. Dhaka Univ J Pharm Sci. 2014;13(2):225–7.CrossRefGoogle Scholar
  39. 39.
    Bispo M, Mourão R, Franzotti E, Bomfim K, Arrigoni-Blank MDF, Moreno M, Marchioro M, Antoniolli A. Antinociceptive and antiedematogenic effects of the aqueous extract of Hyptis pectinata leaves in experimental animals. J Ethnopharmacol. 2001;76(1):81–6.PubMedCrossRefGoogle Scholar
  40. 40.
    Deraedt R, Jouquey S, Delevallée F, Flahaut M. Release of prostaglandins E and F in an algogenic reaction and its inhibition. Eur J Pharmacol. 1980;61(1):17–24.PubMedCrossRefGoogle Scholar
  41. 41.
    Dhara A, Suba V, Sen T, Pal S, Chaudhuri AN. Preliminary studies on the anti-inflammatory and analgesic activity of the methanolic fraction of the root extract of Tragia involucrata Linn. J Ethnopharmacol. 2000;72(1–2):265–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Uche F, Aprioku J. The phytochemical constituents, analgesic and anti-inflammatory effects of methanol extract of Jatropha curcas leaves in Mice and Wister albino rats. Appl Sci Environ Manage. 2008;12(4):99–102.Google Scholar
  43. 43.
    Uddin MMN, Ahmed S, Kabir MSH, Rahman MS, Sultan RA, Emran TB. In vivo analgesic, anti-inflammatory potential in Swiss albino mice and in vitro thrombolytic activity of hydroalcoholic fruits extract from Daemonorops robusta Warb. J Appl Pharm Sci. 2017;7(1):104–13.Google Scholar
  44. 44.
    Chen Y-F, Tsai H-Y, Wu T-S. Anti-inflammatory and analgesic activities from roots of Angelica pubescens. Planta Med. 1995;61(1):2–8.PubMedCrossRefGoogle Scholar
  45. 45.
    Roumestan C, Michel A, Bichon F, Portet K, Detoc M, Henriquet C, Jaffuel D, Mathieu M. Anti-inflammatory properties of desipramine and fluoxetine. Respir Res. 2007;8(1):35.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Damas J, Remacle-Volon G, Deflandre E. Further studies of the mechanism of counter irritation by turpentine. Naunyn Schmiedebergs Arch Pharmacol. 1986;332(2):196–200.PubMedCrossRefGoogle Scholar
  47. 47.
    Dawson J, Sedgwick A, Edwards J, Lees P. A comparative study of the cellular, exudative and histological responses to carrageenan, dextran and zymosan in the mouse. Int J Tissue React. 1991;13(4):171–85.PubMedGoogle Scholar
  48. 48.
    Dudhgaonkar SP, Tandan SK, Bhat AS, Jadhav SH, Kumar D. Synergistic anti-inflammatory interaction between meloxicam and aminoguanidine hydrochloride in carrageenan-induced acute inflammation in rats. Life Sci. 2006;78(10):1044–8.PubMedCrossRefGoogle Scholar
  49. 49.
    Vinegar R, Schreiber W, Hugo R. Biphasic development of carrageenin edema in rats. J Pharmacol Exp Ther. 1969;166(1):96–103.PubMedGoogle Scholar
  50. 50.
    Devi BP, Boominathan R, Mandal SC. Evaluation of antipyretic potential of Cleome viscosa Linn. (Capparidaceae) extract in rats. J Ethnopharmacol. 2003;87(1):11–3.PubMedCrossRefGoogle Scholar
  51. 51.
    Moltz H. Fever: causes and consequences. Neurosci Biobehav Rev. 1993;17(3):237–69.PubMedCrossRefGoogle Scholar
  52. 52.
    Rawlins M, Postgrad R. Mechanism of salicylate-induced antipyresis. In: Pharmacology Thermoregulatory Proceeding Satellite Symposium; 1973. p. 311–24.Google Scholar
  53. 53.
    Rahman MM, Alam AHMK, Sadik G, Islam MR, Proma Khondkar P, Hossain MA, Rashid MA. Antimicrobial and cytotoxic activities of Achyranthes ferruginea. Fitoterapia. 2007;78:260–2.PubMedCrossRefGoogle Scholar
  54. 54.
    Singh A, Singh SK. Molluscicidal evaluation of three common plants from India. Fitoterapia. 2005;76(7–8):747–51.PubMedCrossRefGoogle Scholar
  55. 55.
    Fowles RG, Mootoo BS, Ramsewak RS, Khan A. Toxicity–structure activity evaluation of limonoids from Swietenia species on Artemia salina. Pharm Biol. 2012;50(2):264–7.PubMedCrossRefGoogle Scholar
  56. 56.
    Prasad S, Kashyap RS, Deopujari JY, Purohit HJ, Taori GM, Daginawala HF. Development of an in vitro model to study clot lysis activity of thrombolytic drugs. Thromb J. 2006;4(1):14.Google Scholar
  57. 57.
    Shao W, Brown M. Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy. Breast Cancer Res. 2003;6(1):39.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    McDonnell DP, Norris JD. Connections and regulation of the human estrogen receptor. Science. 2002;296(5573):1642–4.PubMedCrossRefGoogle Scholar
  59. 59.
    Ntie-Kang F, Lifongo LL, Mbah JA, Owono LCO, Megnassan E, Mbaze LM, Judson PN, Sippl W, Efange SM. In silico drug metabolism and pharmacokinetic profiles of natural products from medicinal plants in the Congo basin. Silico Pharmacol. 2013;1(1):12.Google Scholar
  60. 60.
    Fulda S. Betulinic acid for cancer treatment and prevention. Int J Mol Sci. 2008;9(6):1096–107.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Shahriar Ahmed
    • 1
  • Ahmed Rakib
    • 1
  • Md. Ashiqul Islam
    • 1
  • Bibi Humayra Khanam
    • 1
  • Farhana Binta Faiz
    • 1
  • Arkajyoti Paul
    • 2
    • 3
  • Md. Nazim Uddin Chy
    • 2
    • 4
  • N. M. Mahmudul Alam Bhuiya
    • 5
  • Mir Muhammad Nasir Uddin
    • 1
  • S. M. Amanat Ullah
    • 6
  • Md. Atiar Rahman
    • 7
  • Talha Bin Emran
    • 2
    • 7
    • 8
    Email author
  1. 1.Department of Pharmacy, Faculty of Biological ScienceUniversity of ChittagongChittagongBangladesh
  2. 2.Drug Discovery, GUSTO A Research GroupChittagongBangladesh
  3. 3.Department of MicrobiologyJagannath UniversityDhakaBangladesh
  4. 4.Department of PharmacyInternational Islamic University ChittagongChittagongBangladesh
  5. 5.Department of PharmacyJagannath UniversityDhakaBangladesh
  6. 6.Medical Officer, Department of HaematologyChittagong Medical College HospitalChittagongBangladesh
  7. 7.Department of Biochemistry and Molecular BiologyUniversity of ChittagongChittagongBangladesh
  8. 8.Department of PharmacyBGC Trust University BangladeshChittagongBangladesh

Personalised recommendations